110 related articles for article (PubMed ID: 29927772)
1. Pemetrexed-Induced Syncope.
Chapman D; Taj A
Am J Ther; 2019; 26(4):e548-e549. PubMed ID: 29927772
[No Abstract] [Full Text] [Related]
2. Lipodermatosclerosis secondary to pemetrexed use.
Shuster M; Morley K; Logan J; Sequist LV; Shaw A; Fidias P; Kroshinsky D
J Thorac Oncol; 2015 Mar; 10(3):e11-2. PubMed ID: 25695225
[No Abstract] [Full Text] [Related]
3. Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer.
Jung YD; Lee SB; Jung YW; Song JS; Woo IS
Korean J Intern Med; 2017 Sep; 32(5):923-925. PubMed ID: 28298078
[No Abstract] [Full Text] [Related]
4. Pemetrexed and interstitial lung disease.
Adhikari B; Dongol RM; Baral D; Hewett Y; Shah BK
Acta Oncol; 2016; 55(4):521-2. PubMed ID: 26366501
[No Abstract] [Full Text] [Related]
5. Generalized eczema craquelé (asteatotic dermatitis) associated with pemetrexed treatment.
Chu CH; Chou CY; Lin FL
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e81-e83. PubMed ID: 26416293
[No Abstract] [Full Text] [Related]
6. Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Hata A; Katakami N; Hattori Y; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):689-695. PubMed ID: 28280972
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer.
Ikesue H; Watanabe H; Hirano M; Chikamori A; Suetsugu K; Ryokai Y; Egashira N; Yamada T; Ikeda M; Iwama E; Harada T; Takayama K; Nakanishi Y; Masuda S
Biol Pharm Bull; 2015; 38(8):1192-8. PubMed ID: 26235582
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
11. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.
Sbitti Y; Chahdi H; Slimani K; Debbagh A; Mokhlis A; Albouzidi A; Bennani F; Errihani H; Ichou M
J Med Case Rep; 2017 Jul; 11(1):182. PubMed ID: 28750665
[TBL] [Abstract][Full Text] [Related]
12. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
Elsoueidi R; Lander MJ; Richa EM; Adane ED
J Oncol Pharm Pract; 2016 Apr; 22(2):271-4. PubMed ID: 25908647
[TBL] [Abstract][Full Text] [Related]
13. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced inflammation of seborrheic keratoses due to pemetrexed treatment.
Matsudate Y; Murao K; Kubo Y
J Dermatol; 2017 May; 44(5):602-603. PubMed ID: 27345694
[No Abstract] [Full Text] [Related]
15. Pemetrexed-induced acute kidney injury leading to chronic kidney disease.
Chauvet S; Courbebaisse M; Ronco P; Plaisier E
Clin Nephrol; 2014 Dec; 82(6):402-6. PubMed ID: 24424085
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
Takagi Y; Hosomi Y; Nagamata M; Watanabe K; Takahashi S; Nakahara Y; Yomota M; Sunami K; Okuma Y; Shimokawa T; Okamura T
Cancer Chemother Pharmacol; 2016 Mar; 77(3):559-64. PubMed ID: 26821156
[TBL] [Abstract][Full Text] [Related]
17. Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
Schlei Z; Tan W; Faber MG; Chen H; Meagher A; Dy GK
Clin Lung Cancer; 2018 Nov; 19(6):467-475. PubMed ID: 30369425
[TBL] [Abstract][Full Text] [Related]
18. Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models.
Pensec C; Gillaizeau F; Guenot D; Bessard A; Carton T; Leuillet S; Campone M; Neunlist M; Blottière HM; Le Vacon F
Sci Rep; 2020 Jun; 10(1):9094. PubMed ID: 32499509
[TBL] [Abstract][Full Text] [Related]
19. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
20. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
